Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment

被引:117
作者
RostamiHodjegan, A [1 ]
Nurminen, S [1 ]
Jackson, PR [1 ]
Tucker, GT [1 ]
机构
[1] UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
来源
PHARMACOGENETICS | 1996年 / 6卷 / 02期
关键词
caffeine; urine; metabolite ratios; enzyme activity; CYP1A2; NAT2;
D O I
10.1097/00008571-199604000-00001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
At least six urinary metabolite ratios of caffeine have been proposed as probes for in vivo CYP1A2 activity and three for in vivo NAT2 activity. Claims for the frequency distribution of the activity of CYP1A2 based on these empirical ratios have varied from log-normal to trimodal. We have examined the validity of these nine ratios by developing computer simulations using values reported in the literature for the kinetic parameters of caffeine and its metabolites. The results show that the sensitivity of the ratios to confounding variables is, in some cases, greater than their sensitivity to the activity of the enzyme that they are intended to mark. The six CYP1A2 ratios did not exhibit the same pattern of dependency on confounding variables which, in turn, resulted in different shapes of population distributions for each ratio as enzyme activity was varied systematically. Although the dependency of the three NAT2 ratios on confounding variables was less marked, they also showed different patterns of dependency. The outcomes of the simulations were consistent with much of the experimental data on caffeine metabolite ratios. To support the findings from the simulations, simplified equations for each metabolite ratio were derived which emphasize the dominant determinants, With some of the CYP1A2 ratios urine flow was significant to the point where its variance and heterogeneity between populations could lead to spurious detection of polymorphism in CYP1A2 function. Also, if the variability of a dominant confounding factor was high and sensitivity of the ratio to intrinsic CYP1A2 activity was low, any polymorphism in the latter would be obscured. When a specific time interval was defined for urine collection, this time was shown to be a critical factor in the ability to discriminate bimodality in some of the ratios, when a marked polymorphism in enzyme activity was assumed. Those ratios which have shown no evidence for bimodality in CYP1A2 function in experimental studies are inherently more discriminant of such heterogeneity compared to those ratios which have been claimed to detect polymorphism of CYP1A2 from experimental data. While recommending a 'best buy' from amongst the caffeine urinary metabolite ratios, we favour plasma/saliva indices (caffeine half-life or paraxanthine/caffeine ratio in a spot sample).
引用
收藏
页码:121 / 149
页数:29
相关论文
共 69 条
[1]  
BALOGH A, 1992, INT J CLIN PHARM TH, V30, P383
[2]   BLACK (AIR-CURED) AND BLOND (FLUE-CURED) TOBACCO CANCER RISK .4. MOLECULAR DOSIMETRY STUDIES IMPLICATE AROMATIC-AMINES AS BLADDER CARCINOGENS [J].
BARTSCH, H ;
MALAVEILLE, C ;
FRIESEN, M ;
KADLUBAR, FF ;
VINEIS, P .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (08) :1199-1207
[3]  
BARTSCH H, 1990, J NATL CANCER I, V82, P1825
[4]   A POPULATION AND FAMILY STUDY OF N-ACETYLTRANSFERASE USING CAFFEINE URINARY METABOLITES [J].
BECHTEL, YC ;
BONAITIPELLIE, C ;
POISSON, N ;
MAGNETTE, J ;
BECHTEL, PR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (02) :134-141
[5]   INTERACTION BETWEEN 2 PROBES USED FOR PHENOTYPING CYTOCHROMES P4501A2 (CAFFEINE) AND P4502E1 (CHLORZOXAZONE) IN HUMANS [J].
BERTHOU, F ;
GOASDUFF, T ;
LUCAS, D ;
DREANO, Y ;
LEBOT, MH ;
MENEZ, JF .
PHARMACOGENETICS, 1995, 5 (02) :72-79
[6]   SECONDARY METABOLISM OF THEOPHYLLINE BIOTRANSFORMATION PRODUCTS IN MAN - ROUTE OF FORMATION OF 1-METHYLURIC ACID [J].
BIRKETT, DJ ;
MINERS, JO ;
ATTWOOD, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 (01) :117-119
[7]   THE ABSOLUTE BIOAVAILABILITY OF CAFFEINE IN MAN [J].
BLANCHARD, J ;
SAWERS, SJA .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (01) :93-98
[8]   CAFFEINE DISPOSITION AFTER ORAL DOSES [J].
BONATI, M ;
LATINI, R ;
GALLETTI, F ;
YOUNG, JF ;
TOGNONI, G ;
GARATTINI, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (01) :98-106
[9]   DETERMINATION OF CYP1A2 AND NAT2 PHENOTYPES IN HUMAN-POPULATIONS BY ANALYSIS OF CAFFEINE URINARY METABOLITES [J].
BUTLER, MA ;
LANG, NP ;
YOUNG, JF ;
CAPORASO, NE ;
VINEIS, P ;
HAYES, RB ;
TEITEL, CH ;
MASSENGILL, JP ;
LAWSEN, MF ;
KADLUBAR, FF .
PHARMACOGENETICS, 1992, 2 (03) :116-127
[10]  
CALLAHAN MM, 1993, DRUG MET DISPOS, V11, P211